Overcoming cancer therapy resistance: From drug innovation to therapeutics
Top Cited Papers
- 8 March 2025
- journal article
- review article
- Published by Elsevier in Drug Resistance Updates
- Vol. 81, 101229
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82373710, 82404383, 82103985)
- Jiangsu Commission of Health (ZD 2021040)
This publication has 266 references indexed in Scilit:
- Nanomedicine Tumor TargetingAdvanced Materials, 2024
- Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsJAMA Network Open, 2024
- Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular CarcinomaJAMA Oncology, 2024
- Targeted Reprogramming of Vitamin B3 Metabolism as a Nanotherapeutic Strategy towards Chemoresistant CancersAdvanced Materials, 2023
- US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018JAMA Network Open, 2022
- Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine KinaseAngewandte Chemie International Edition, 2021
- Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challengesCancer Communications, 2021
- New Promise and Opportunities for Allosteric Kinase InhibitorsAngewandte Chemie International Edition, 2019
- Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular CarcinomaHepatology, 2019
- Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistryMedicinal Research Reviews, 2018